Pamalican Asset Management Ltd Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS)

Pamalican Asset Management Ltd purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 30,000 shares of the company’s stock, valued at approximately $771,000.

Other hedge funds have also recently modified their holdings of the company. Frazier Life Sciences Management L.P. grew its position in NewAmsterdam Pharma by 5.1% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock worth $213,396,000 after purchasing an additional 628,251 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of NewAmsterdam Pharma by 291.9% during the fourth quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock valued at $102,763,000 after buying an additional 2,978,263 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of NewAmsterdam Pharma by 2,410.4% during the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company’s stock valued at $59,499,000 after buying an additional 2,222,900 shares during the last quarter. Alliancebernstein L.P. purchased a new position in NewAmsterdam Pharma in the 4th quarter worth $47,752,000. Finally, Janus Henderson Group PLC raised its stake in NewAmsterdam Pharma by 51.1% in the 3rd quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock worth $25,607,000 after acquiring an additional 520,772 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ NAMS opened at $18.00 on Friday. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -6.92 and a beta of -0.04. The firm’s 50 day simple moving average is $21.29 and its 200-day simple moving average is $21.27. NewAmsterdam Pharma has a 12 month low of $15.19 and a 12 month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. Analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on NAMS shares. Scotiabank increased their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Thursday, February 27th. Royal Bank of Canada reissued an “outperform” rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Needham & Company LLC cut their price objective on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma currently has an average rating of “Buy” and a consensus target price of $43.33.

Insider Activity at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the transaction, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. This trade represents a 90.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James N. Topper purchased 4,005 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was bought at an average cost of $21.02 per share, with a total value of $84,185.10. Following the acquisition, the director now owns 3,012,434 shares in the company, valued at $63,321,362.68. This represents a 0.13 % increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is owned by company insiders.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.